Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Breakthrough Research that Help Address Complex Diseases and Offer Diverse Treatments - Research Report on Medivation, Jazz, NPS, Infinity and Halozyme

PR Newswire June 27, 2013

Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

PR Newswire June 26, 2013

New Research Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis

PR Newswire June 13, 2013

New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis

PR Newswire June 5, 2013

New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis

PR Newswire June 5, 2013

The Zacks Analyst Blog Highlights: Roche Holding, Bayer, Conceptus, Teva Pharmaceutical Industries and Jazz Pharmaceuticals Public

PR Newswire May 31, 2013

The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz Pharmaceuticals

PR Newswire May 23, 2013

Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

PR Newswire May 13, 2013

Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

PR Newswire May 13, 2013

JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS

PR Newswire May 7, 2013

JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS

PR Newswire May 7, 2013

Jazz Pharmaceuticals To Report First Quarter 2013 Financial Results On May 7, 2013

PR Newswire April 23, 2013

Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders

PR Newswire March 5, 2013

Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders

PR Newswire March 4, 2013

Daytraders Dominate Markets With 98.5% Profitable "Stock Alert" Trades

Marketwired February 28, 2013

Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March

PR Newswire February 27, 2013

Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results

PR Newswire February 26, 2013

Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

Business Wire February 26, 2013

Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013

PR Newswire February 11, 2013

The Reason It Trades, What's Moving CS, JAZZ, WNC and ALE

Marketwired January 30, 2013